Pentazocine Lactate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IM/SC	1-3 mg/kg	q4-6h	Duration: As needed for pain Notes: May cause dysphoria; use with caution. For premedication, lower doses (0.5-1 mg/kg) may be used.
Cat	IM/SC	1-3 mg/kg	q4-6h	Duration: As needed for pain Notes: Cats may exhibit excitement; use with caution.
Horse	IV/IM	0.3-0.5 mg/kg	q4-6h	Duration: As needed for pain Notes: May cause ataxia and excitement; use with caution.
Cattle	IM/SC	1-3 mg/kg	q4-6h	Duration: As needed for pain Notes: Not approved for food animals; extra-label use requires withdrawal times.
Small Ruminants	IM/SC	1-3 mg/kg	q4-6h	Duration: As needed for pain Notes: Limited data; use with caution.
Rabbit	IM/SC	5-10 mg/kg	q4-6h	Duration: As needed for pain Notes: Limited data; may cause sedation or excitement.

Clinical Indications & Species Uses

General Indications

Mild to moderate analgesia
Preanesthetic medication
Adjunct to anesthesia

Dog (Canine)

Analgesia for mild to moderate pain
Preanesthetic medication
Sedation (in combination with tranquilizers)

Cat (Feline)

Analgesia for mild to moderate pain
Preanesthetic medication
Sedation (in combination with tranquilizers)

Horse (Equine)

Analgesia for mild to moderate pain
Sedation (in combination with alpha-2 agonists)

Cattle (Bovine)

Analgesia for mild to moderate pain
Sedation (in combination with tranquilizers)

Small Ruminants (Sheep / Goat)

Analgesia for mild to moderate pain
Sedation (in combination with tranquilizers)

Rabbit & Small Mammals

Analgesia for mild to moderate pain (limited data)

Pharmacology & Mechanism of Action

Drug Class: Opioid Analgesic (Mixed Agonist-Antagonist) | Pharmacological Group: Benzomorphan derivative; opioid analgesic with weak mu-receptor antagonism and kappa-receptor agonism

Mechanism of Action: Pentazocine is a mixed agonist-antagonist opioid. It acts as an agonist at kappa (κ) opioid receptors and as a weak antagonist or partial agonist at mu (μ) opioid receptors. The analgesic effect is primarily mediated through κ-receptor activation, which produces spinal and supraspinal analgesia. Additionally, it inhibits the reuptake of norepinephrine and serotonin, contributing to its analgesic action. Its antagonist activity at μ receptors can precipitate withdrawal in patients physically dependent on pure μ agonists.

Pharmacodynamics: Pentazocine produces analgesia, sedation, and respiratory depression (ceiling effect). It has a lower abuse potential compared to pure μ agonists. In veterinary species, it provides moderate analgesia, but its efficacy is limited compared to full agonists like morphine. It may cause dysphoria in some animals, especially at higher doses. Cardiovascular effects include increased heart rate and blood pressure due to increased sympathetic tone.

⚡ Pharmacokinetics Summary

Absorption: After oral administration, pentazocine undergoes extensive first-pass metabolism, resulting in low bioavailability (approximately 20% in humans). In veterinary species, oral absorption is variable; parenteral administration (IM/SC) provides more reliable absorption. Onset of action after IM injection is within 15-30 minutes.

Distribution: Pentazocine is widely distributed in tissues, with high concentrations in the liver, kidneys, and lungs. It crosses the blood-brain barrier and placenta. Protein binding is approximately 60-70% in humans, but may vary in animals.

Metabolism: Extensively metabolized in the liver, primarily by oxidation and glucuronidation. Major metabolites include norpentazocine and pentazocine glucuronide. In animals, metabolism may be species-dependent; for example, horses may have different metabolic pathways.

Excretion: Excreted primarily in urine (about 60-70% as metabolites and unchanged drug) and to a lesser extent in feces. Renal excretion is pH-dependent; acidic urine increases elimination.

Half-Life: Dogs: approximately 1.5-2 hours; Cats: approximately 1-2 hours; Horses: approximately 1-2 hours; Humans: 2-3 hours.

Bioavailability: Oral: low (20% in humans); IM/SC: high (near 100%).

Protein Binding: Approximately 60-70% (human data; may vary in animals).

Available Formulations & Strengths

Injectable Solution 30 mg/mL (as lactate) (IM/SC/IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to pentazocine or other opioids
Severe respiratory depression
Acute or severe hepatic impairment
Use in animals with head trauma or increased intracranial pressure (may increase ICP)
Concurrent use with pure mu agonists (may precipitate withdrawal)
Use in animals with a history of opioid abuse (rare in veterinary medicine)

Warnings & Clinical Precautions:

Use with caution in animals with renal or hepatic disease
May cause respiratory depression; monitor respiratory rate
May cause dysphoria or excitement, especially in cats and horses
Use with caution in animals with cardiac disease or hypotension
May cause sedation; avoid concurrent use with other CNS depressants
In food animals, observe withdrawal times; extra-label use requires veterinary oversight
Use with caution in pregnant or lactating animals; safety not established

Adverse Effects & Reactions

Common:

Sedation
Dysphoria
Vomiting
Salivation
Ataxia

Serious / Severe:

Respiratory depression
Seizures (rare)
Cardiovascular collapse (rare)
Anaphylaxis (rare)

Rare:

Hypotension
Hypertension
Tachycardia
Urinary retention
Constipation

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Pure mu opioid agonists (e.g., morphine, fentanyl)	Pentazocine may antagonize the analgesic effects of mu agonists and precipitate withdrawal in physically dependent animals.	High
CNS depressants (e.g., barbiturates, benzodiazepines, phenothiazines)	Additive CNS depression and respiratory depression.	Moderate
MAO inhibitors	Potential for hypertensive crisis or serotonin syndrome.	Moderate
Tricyclic antidepressants	May increase risk of seizures or cardiovascular effects.	Moderate
Anticholinergic agents	May increase risk of urinary retention and constipation.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Respiratory depression
CNS depression or excitation
Seizures
Hypotension or hypertension
Tachycardia
Hypothermia

Emergency Treatment Protocol: Provide supportive care. Maintain airway and assist ventilation if needed. Administer oxygen. For respiratory depression, consider naloxone (0.01-0.04 mg/kg IV, may need repeated doses). Monitor vital signs. Treat seizures with diazepam or barbiturates if severe. Provide fluid therapy for hypotension. Since pentazocine has a ceiling effect on respiratory depression, overdose may be less severe than with pure agonists, but still requires aggressive management.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 4 days

Extra-label use in food animals requires extended withdrawal times; consult FARAD for specific recommendations. These are general estimates; actual withdrawal times may vary.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep in tightly closed container. Do not freeze.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not FDA-approved for veterinary use, but may be used extra-label.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with veterinary oversight, but requires extended withdrawal times. In non-food animals, extra-label use is common. In the EU, similar regulations apply under Cascade.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pentazocine lactate is a mixed agonist-antagonist opioid that provides moderate analgesia in veterinary patients. It is less potent than morphine and has a ceiling effect on respiratory depression, making it potentially safer in some situations. However, it can cause dysphoria and excitement, particularly in cats and horses. It is often used as a preanesthetic or for short-term pain management. Due to its antagonist activity at mu receptors, it should not be used concurrently with pure mu agonists. In food animals, extra-label use requires careful consideration of withdrawal times. Overall, its use in veterinary medicine has declined with the availability of more effective and safer analgesics, but it may still be used in certain situations.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)